Emerging role of cell-free DNA in kidney transplantation

Table 2 Trials of donor-derived cell-free DNA in kidney transplantation

NCT02424227	Noninvasive blood test to diagnose acute rejection after kidney transplantation (DART)	Completed
NCT03765203	Utility of a novel dd-cfDNA test to detect injury in renal posttransplant patients (QIDNEY)	Completed
NCT03326076	Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR)	Recruiting
NCT04091984	The Prospera kidney transplant active rejection assessment registry (ProActive)	Recruiting
NCT04057742	Allosure for the monitoring of antibody-mediated processes after kidney transplantation (All-MAP)	Recruiting
NCT03759535	Study in detection cfDNA for the early stage diagnosis of acute rejection post-renal transplantation	Not yet recruiting
NCT03984747	Study for the prediction of active rejection in organs using donor-derived cell-free DNA detection (SPARO)	Recruiting
NCT04130685	Donor-derived cell-free DNA for surveillance in simultaneous pancreas and kidney transplant recipients	Recruiting
NCT04166149	Eliminating the need for pancreas biopsy using peripheral blood cell-free DNA (PancDX)	Recruiting
NCT03859388	Longitudinal changes in donor-derived cell-free DNA with tocilizumab treatment for chronic antibody-mediated rejection	Enrolling
NCT04225988	Comparison of tacrolimus extended-release (envarsus xr) to tacrolimus immediate-release in HLA sensitized kidney transplant recipients	Recruiting
NCT04177095	Immune monitoring to facilitate belatacept monotherapy	Recruiting
NCT04239703	Intercomex donor-derived cell-free DNA study	Recruiting

dd-cfDNA: Donor-derived cell-free DNA; HLA: Human leukocyte antigen.